Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW R&D COMPANY (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) For Immediate Release Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion Share as Stock Dividend Actelion R&D Unit to Spin Out into Standalone Company Based and Listed in Switzerland; New R&D Company to Continue Actelion's Successful Culture of Innovation and Johnson & Johnson to Hold Substantial Minority Interest Acquisition Expected to Accelerate Johnson & Johnson Revenue and Earnings Growth Rates; Immediately Accretive to Johnson & Johnson Adjusted Earnings Per Share Brings Actelion's Complementary Market-Leading Medicines and Promising Advanced...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>